Terapia objawowa stwardnienia rozsianego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2012
Słowa kluczowe:
terapia objawowa, stwardnienie rozsiane
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie stwardnienia rozsianego (SM) lekami immunomodulacyjnymi może mieć znaczący wpływ na naturalny przebieg choroby. Pomimo tego pacjenci doświadczają licznych objawów choroby wynikających z rozsianego uszkodzenia ośrodkowego układu nerwowego. Celem terapii objawowej jest wyeliminowanie lub zmniejszenie objawów wpływających ujemnie na jakość życia chorych. W pracy podsumowano leczenie najważniejszych objawów SM.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Dla pacjenta
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Sadownick A.D., Ebers G.C.: Epidemiology of multiple sclerosis: A critical overview. Can. J. Neurol. Sci. 1993; 20: 17-29.
2. Brichetto G., Messmer Ucelli M., Mancardi G.L. et al.: Symptomatic medication use in multiple sclerosis. Mult. Scler. 2003; 9: 458-60.
3. Henze T., Rieckmann P., Toyka K.V.: Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol. 2006; 56: 78-105.
4. Shakespeare D.T., Craig J., Lloyd M.: Spasticity and movement. Int. MSJ 2001; 7: 93-99.
5. Stolp-Smith K., Wainberg M.: Antidepressant exacerbation of spasticity. Arch. Phys. Med. Rehabil. 1999; 80: 339-42.
6. Haselkorn J.K., Balsdon R.C., Fry W.D. et al.: Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J. Spinal. Cord. Med. 2005; 28: 167-199.
7. Mueller M.E., Gruenthal M., Olson W.L. et al.: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch. Phys. Med. Rehabil. 1997; 78: 521-24.
8. Cutter N.C., Scott D.D., Johnson J.C. et al.: Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch. Phys. Med. Rehabil. 2000; 81: 164-69.
9. Zajicek J., Fox P., Sanders H. et al.: UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-26.
10. Vaney C., Heinzel-Gutenbrunner M., Jobin P. et al.: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 2004; 10: 417-424.
11. Wade D.T., Makela P., Robson P. et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 2004; 10: 434-441.
12. Wade D.T., Collin C., Stott C., Duncombe P.: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 2010; 16: 707-714.
13. Hyman N., Barnes M., Bhakta B. et al.: Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomized, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry 2000; 68: 707-712.
14. Miller L., Mattison P., Paul L. et al.: The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult. Scler. 2007; 13: 527-533.
15. Krupp L.B.: Mechanism, measurement, and management of fatigue in multiple sclerosis. W: Multiple sclerosis: clinical challenges and controversies. Thompson A.J., Polman C., Reinhard H. (red.). Martin Dunitz, London 1997: 283-94.
16. Fisk J.D., Pontefract A., Ritvo P.G. et al.: The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci. 1994; 21: 9-14.
17. Comi G., Leocani L., Rossi P. et al.: Physiopathology and treatment of fatigue in multiple sclerosis. J. Neurol. 2001; 248: 174-79.
18. Bergamaschi R., Romani A., Versino M. et al.: Clinical aspects of fatigue in multiple sclerosis. Funct. Neurol. 1997; 12: 247-51.
19. Krupp L.B., Rizvi S.A.: Symptomatic therapy for under recognized manifestation of multiple sclerosis. Neurology 2002; 58: S32-S39.
20. De Sa J.C., Airas L., Bartholome E. et al.: Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther. Adv. Neurol. Disord. 2011 May; 4(3): 139-68.
21. Weinshenker B.G., Penman M., Bass B. et al.: A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471.
22. Krupp L.B., Coyle P.K., Doscher C. et al.: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-1961.
23. Rammohan K.W., Rosenberg J.H., Lynn D.J. et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J. Neurol. Neurosurg. Psychiatry 2002; 72: 179-183.
24. Stankoff B., Waubant E., Confavreux C. et al.: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64: 1139-1143.
25. Goodman A.D., Brown T.R., Krupp L.B. et al.: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738.
26. Sadovnick A.D., Remick R.A., Allen J. et al.: Depression and multiple sclerosis. Neurology 1996; 46: 628-632.
27. Sadovnick A.D., Eisen K., Ebers G.C. et al.: Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-1196.
28. Schiffer R.B., Caine E.D., Bamford K.A. et al.: Depressive episodes in patients with multiple sclerosis. Am. J. Psychiatry 1983; 140: 1498-1500.
29. Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. et al.: Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010; 177: 323-329.
30. Mohr D.C., Boudewyn A.C., Goodkin D.E. et al.: Comparative outcomes for individual cognitive-behavior therapy, supportive–expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Consult. Clin. Psychol. 2001; 69: 942-949.
31. Blaivas J.G.: Management of bladder dysfunction in multiple sclerosis. Neurology 1980; 30: 12-18.
32. Frontoni M., Giubilei F.: Autonomic dysfunction in MS. Int. MSJ 1999; 6: 79-87.
33. Bakke A., Myrh K., Gronning M. et al.: Bladder, bowel and sexual dysfunction in patients with multiple sclerosis – a cohort study. Scand. J. Urol. Nephrol. Suppl. 1996; 179: 61-66.
34. Kessler T.M., Fowler C.J., Panicker J.N.: Sexual dysfunction in multiple sclerosis. Rev. Neurother. Expert 2009; 9: 341-350.
35. Fraser C., Mahoney J., McGurl J.: Correlates of sexual dysfunction in men and women with multiple sclerosis. J. Neurosci. Nurs. 2008; 40: 312-317.
36. Ghezzi A.: Sexual dysfunction in multiple sclerosis. Int. MSJ 1999; 5: 45-53.
37. Ghezzi A., Zaffaroni M., Baldini S. et al.: Sexual dysfunction in multiple sclerosis male patients in relation to clinical findings. Eur. J. Neurol. 1996; 3: 462-66.
38. Shifren J.L.: The role of androgens in female sexual dysfunction. Mayo Clin. Proc. 2004; 79: S19-S24.
39. Lopez del Val L.J., Santos S.: Gabapentin in the treatment of tremor. Rev. Neurol. 2003; 36: 322-26.
40. Yap L., Kouyialis A., Varma T.R.: Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br. J. Neurosurg. 2007; 21: 349-354.
41. Alusi S.H., Worthington J., Glickman S. et al.: A study of tremor in multiple sclerosis. Brain 2001; 124: 720-30.
42. Herrera W.G.: Vestibular and other balance disorders in multiple sclerosis. Neurol. Clin. 1990; 8: 407-20.
43. Paty D.W., Noseworthy J.H., Ebers G.C.: Diagnosis of multiple sclerosis. W: Multiple sclerosis. Paty D.W., Ebers G.C. (red.). F.A. Davis Company 1997: 437-449.
44. DeSousa E.A., Albert R.H., Kalman B.: Cognitive impairments in multiple sclerosis: a review. Am. J. Alzheimers Dis. Other. Demen. 2002; 17: 23-29.
45. Amato M.P., Ponziani G., Siracusa G. et al.: Cognitive dysfuntion in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol. 2001; 58: 1602-6.
46. Rao S.M., Leo G.J., Bernardin L. et al.: Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-91.
47. Villoslada P., Arrondo G., Sepulcre J. et al.: Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009; 72: 1630-1633.
48. Huolman S., Hämäläinen P., Vorobyev V. et al.: The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult. Scler. 2011 Nov; 17(11): 1351-61.
49. Putzki N., Pfriem A., Limmroth V. et al.: Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur. J. Neurol. 2009; 16: 262-267.
2. Brichetto G., Messmer Ucelli M., Mancardi G.L. et al.: Symptomatic medication use in multiple sclerosis. Mult. Scler. 2003; 9: 458-60.
3. Henze T., Rieckmann P., Toyka K.V.: Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol. 2006; 56: 78-105.
4. Shakespeare D.T., Craig J., Lloyd M.: Spasticity and movement. Int. MSJ 2001; 7: 93-99.
5. Stolp-Smith K., Wainberg M.: Antidepressant exacerbation of spasticity. Arch. Phys. Med. Rehabil. 1999; 80: 339-42.
6. Haselkorn J.K., Balsdon R.C., Fry W.D. et al.: Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J. Spinal. Cord. Med. 2005; 28: 167-199.
7. Mueller M.E., Gruenthal M., Olson W.L. et al.: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch. Phys. Med. Rehabil. 1997; 78: 521-24.
8. Cutter N.C., Scott D.D., Johnson J.C. et al.: Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch. Phys. Med. Rehabil. 2000; 81: 164-69.
9. Zajicek J., Fox P., Sanders H. et al.: UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-26.
10. Vaney C., Heinzel-Gutenbrunner M., Jobin P. et al.: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 2004; 10: 417-424.
11. Wade D.T., Makela P., Robson P. et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 2004; 10: 434-441.
12. Wade D.T., Collin C., Stott C., Duncombe P.: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 2010; 16: 707-714.
13. Hyman N., Barnes M., Bhakta B. et al.: Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomized, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry 2000; 68: 707-712.
14. Miller L., Mattison P., Paul L. et al.: The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult. Scler. 2007; 13: 527-533.
15. Krupp L.B.: Mechanism, measurement, and management of fatigue in multiple sclerosis. W: Multiple sclerosis: clinical challenges and controversies. Thompson A.J., Polman C., Reinhard H. (red.). Martin Dunitz, London 1997: 283-94.
16. Fisk J.D., Pontefract A., Ritvo P.G. et al.: The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci. 1994; 21: 9-14.
17. Comi G., Leocani L., Rossi P. et al.: Physiopathology and treatment of fatigue in multiple sclerosis. J. Neurol. 2001; 248: 174-79.
18. Bergamaschi R., Romani A., Versino M. et al.: Clinical aspects of fatigue in multiple sclerosis. Funct. Neurol. 1997; 12: 247-51.
19. Krupp L.B., Rizvi S.A.: Symptomatic therapy for under recognized manifestation of multiple sclerosis. Neurology 2002; 58: S32-S39.
20. De Sa J.C., Airas L., Bartholome E. et al.: Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther. Adv. Neurol. Disord. 2011 May; 4(3): 139-68.
21. Weinshenker B.G., Penman M., Bass B. et al.: A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471.
22. Krupp L.B., Coyle P.K., Doscher C. et al.: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-1961.
23. Rammohan K.W., Rosenberg J.H., Lynn D.J. et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J. Neurol. Neurosurg. Psychiatry 2002; 72: 179-183.
24. Stankoff B., Waubant E., Confavreux C. et al.: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64: 1139-1143.
25. Goodman A.D., Brown T.R., Krupp L.B. et al.: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738.
26. Sadovnick A.D., Remick R.A., Allen J. et al.: Depression and multiple sclerosis. Neurology 1996; 46: 628-632.
27. Sadovnick A.D., Eisen K., Ebers G.C. et al.: Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-1196.
28. Schiffer R.B., Caine E.D., Bamford K.A. et al.: Depressive episodes in patients with multiple sclerosis. Am. J. Psychiatry 1983; 140: 1498-1500.
29. Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. et al.: Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010; 177: 323-329.
30. Mohr D.C., Boudewyn A.C., Goodkin D.E. et al.: Comparative outcomes for individual cognitive-behavior therapy, supportive–expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Consult. Clin. Psychol. 2001; 69: 942-949.
31. Blaivas J.G.: Management of bladder dysfunction in multiple sclerosis. Neurology 1980; 30: 12-18.
32. Frontoni M., Giubilei F.: Autonomic dysfunction in MS. Int. MSJ 1999; 6: 79-87.
33. Bakke A., Myrh K., Gronning M. et al.: Bladder, bowel and sexual dysfunction in patients with multiple sclerosis – a cohort study. Scand. J. Urol. Nephrol. Suppl. 1996; 179: 61-66.
34. Kessler T.M., Fowler C.J., Panicker J.N.: Sexual dysfunction in multiple sclerosis. Rev. Neurother. Expert 2009; 9: 341-350.
35. Fraser C., Mahoney J., McGurl J.: Correlates of sexual dysfunction in men and women with multiple sclerosis. J. Neurosci. Nurs. 2008; 40: 312-317.
36. Ghezzi A.: Sexual dysfunction in multiple sclerosis. Int. MSJ 1999; 5: 45-53.
37. Ghezzi A., Zaffaroni M., Baldini S. et al.: Sexual dysfunction in multiple sclerosis male patients in relation to clinical findings. Eur. J. Neurol. 1996; 3: 462-66.
38. Shifren J.L.: The role of androgens in female sexual dysfunction. Mayo Clin. Proc. 2004; 79: S19-S24.
39. Lopez del Val L.J., Santos S.: Gabapentin in the treatment of tremor. Rev. Neurol. 2003; 36: 322-26.
40. Yap L., Kouyialis A., Varma T.R.: Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br. J. Neurosurg. 2007; 21: 349-354.
41. Alusi S.H., Worthington J., Glickman S. et al.: A study of tremor in multiple sclerosis. Brain 2001; 124: 720-30.
42. Herrera W.G.: Vestibular and other balance disorders in multiple sclerosis. Neurol. Clin. 1990; 8: 407-20.
43. Paty D.W., Noseworthy J.H., Ebers G.C.: Diagnosis of multiple sclerosis. W: Multiple sclerosis. Paty D.W., Ebers G.C. (red.). F.A. Davis Company 1997: 437-449.
44. DeSousa E.A., Albert R.H., Kalman B.: Cognitive impairments in multiple sclerosis: a review. Am. J. Alzheimers Dis. Other. Demen. 2002; 17: 23-29.
45. Amato M.P., Ponziani G., Siracusa G. et al.: Cognitive dysfuntion in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol. 2001; 58: 1602-6.
46. Rao S.M., Leo G.J., Bernardin L. et al.: Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-91.
47. Villoslada P., Arrondo G., Sepulcre J. et al.: Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009; 72: 1630-1633.
48. Huolman S., Hämäläinen P., Vorobyev V. et al.: The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult. Scler. 2011 Nov; 17(11): 1351-61.
49. Putzki N., Pfriem A., Limmroth V. et al.: Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur. J. Neurol. 2009; 16: 262-267.